Exploitation of transporters to develop novel antimicrobials against Gram-negative bacteria

点击翻译按钮获取中文摘要

We need new classes of antibiotics because multi-drug resistant (MDR) bacteria are threatening our ability to treat infectious disease. The UK government estimates that without new antibiotics infectious disease will cost the global economy $100 trillion by 2050. Discuva’s innovative (and proprietary) technology (SATIN) is a proven platform for the discovery of new antibiotics; SATIN has already delivered new antibacterial compounds with novel mechanisms-of-action and within our lead programme clinical trials are planned in 2017 for the treatment of MDR gonorrhoea. This project will use this UK invented technology to deliver improved antibiotics which are both highly active against some of the most resistant bacteria causing disease and have a reduced likelihood of selecting resistance compared to conventional antibiotics. This will address the issue of clinical failure associated with the most resistant and life-threatening bacterial infections including E. coli. Ultimately, this project has potential for significant benefits to patients, the NHS (and health care systems globally), and the antibiotc research community.